ARCHIVES

Progression-free survival as a primary endpoint for drug approval requires prospective planning, FDA’s Pazdur says.

This article is from The Cancer Letter archive.

Vol. 30 No. 19 | May 7, 2004

Download PDF Visit The Full Archive

Related Articles

NIH Tells Grant Applicants One Resubmission Is Enough.

October 24, 2008

ASCO 2014: Special Awards

May 30, 2014

NCI Won’t Recognize Wolmark Wile NSABP is Plaintiff In Suit

November 18, 1994

Trials Could Start Earlier If Model Contract Language Adopted, NCI and CEO Roundtable Say.

December 12, 2008

NCI Asks Centers To Limit Increases In Applying For Support Grant Renewals.

October 12, 2001

Development Of New Screening System For Antimetastasis Drugs Approved

June 25, 1982